2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2021, 20: e74-e88. PMID: 33640480, PMCID: PMC8384969, DOI: 10.1016/j.cgh.2021.02.032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSerious infectionsMarginal structural Cox proportional hazards modelsCox proportional hazards modelBaseline disease characteristicsRetrospective cohort studyAdministrative claims databaseProportional hazards modelTime-varying useCohort studyBowel diseaseTreatment initiationUlcerative colitisHealthcare utilizationClaims databaseDisease characteristicsTumor necrosisVedolizumabLower riskHazards modelPatientsInfectionAntagonistInsurance coverageRisk
2020
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort studyFewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham NS, Yang EH, Noseworthy PA, Inselman J, Yao X, Herrin J, Sangaralingham LR, Ngufor C, Shah ND. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Alimentary Pharmacology & Therapeutics 2020, 52: 646-654. PMID: 32657466, PMCID: PMC8183594, DOI: 10.1111/apt.15790.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedClopidogrelCohort StudiesFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative ComplicationsPrasugrel HydrochlorideRetrospective StudiesThromboembolismTicagrelorTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionAcute coronary syndromeGIB ratesGIB riskCoronary syndromeGastrointestinal bleedingSTEMI patientsCoronary interventionHazard ratioMajor adverse cardiac eventsRisk reductionCox proportional hazards modelNSTE-ACS patientsAdverse cardiac eventsMajor bleeding eventsConfidence intervalsInverse probability treatmentProportional hazards modelMedicare Advantage enrolleesBleeding eventsClopidogrel prescriptionGIB eventsNSTE-ACSGastrointestinal bleedBaseline characteristics